Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

Rachel Jones, Jan Willem Cohen Tervaert, Thomas Häuser et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16